Tumor lysis with LTX-401 creates anticancer immunity

Photodynamic therapy with redaporfin targets the endoplasmic reticulum and Golgi apparatus

(2018) Lígia C Gomes‐da‐Silva et al.   EMBO JOURNAL

Recruitment of LC3 to damaged Golgi apparatus

(2018) Lígia C. Gomes-da-Silva et al.   CELL DEATH AND DIFFERENTIATION

Oncolysis with DTT-205 and DTT-304 generates immunological memory in cured animals

(2018) Heng Zhou et al.   Cell Death & Disease

LTX-315: a first-in-class oncolytic peptide that reprograms the tumor microenvironment

(2017) Baldur Sveinbjørnsson et al.   Future Medicinal Chemistry

Oncolytic peptide LTX-315 induces an immune-mediated abscopal effect in a rat sarcoma model

(2017) Janne Nestvold et al.   OncoImmunology

The oncolytic compound LTX-401 targets the Golgi apparatus

(2016) Heng Zhou et al.   CELL DEATH AND DIFFERENTIATION

The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade

(2016) T Yamazaki et al.   CELL DEATH AND DIFFERENTIATION

The Cytolytic Amphipathic β(2,2)-Amino Acid LTX-401 Induces DAMP Release in Melanoma Cells and Causes Complete Regression of B16 Melanoma

(2016) Liv-Marie Eike et al.   PLoS One

The oncolytic peptide LTX-315 triggers immunogenic cell death

(2016) H Zhou et al.   Cell Death & Disease

The oncolytic peptide LTX-315 kills cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilization

(2015) Heng Zhou et al.   Oncotarget

LTX-315 (Oncopore™)

(2014) Ketil André Camilio et al.   OncoImmunology